However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

Roche Holding AG (ROG.VX) said Thursday its experimental diabetes drug taspoglutide worked better than a rival drug sold by Eli Lilly & Co. (LLY) in lowering blood sugar, according to the results ...